Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 3 2Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Vomiting 1Nausea 1Multiple Myeloma 1

Interventions

Cyclophosphamide 10fludarabine 8Dexamethasone 8Lenalidomide 6Bortezomib 5Granulocyte Colony-Stimulating Factor 468Ga-pentixafor 4Melphalan 3Filgrastim 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Blood Specimen Collection 2tocilizumab 1selinexor 1ruxolitinib 1pomalidomide 1pembrolizumab 1methyl prednisolonate 1ixazomib 1ioversol 1inebilizumab 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Aprepitant × Plasma cell × Clear all
NCT00314743 2013-05-24

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

Washington University School of Medicine

Phase EARLY_PHASE1 Completed
48 enrolled
Plasma cell

Multiple Myeloma, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡